In this issue:
Improved OS of patients with melanoma brain metastases
Safety of resuming anti-PD-1 in patients with irAEs during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Bevacizumab treatment for radiation necrosis
Association of Immunotherapy with OS in elderly patients with melanoma
Neoadjuvant plus adjuvant dabrafenib + trametinib vs standard of care in patients with high-risk, surgically resectable melanoma
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression
Efficacy and safety outcomes in advanced melanoma patients who discontinued treatment with nivolumab + ipilimumab because of AEs
SNL biopsy and management of regional lymph nodes in melanoma: ASCO-SSO practice guideline update
LMR is associated with survival in pembrolizumab-treated metastatic melanoma
OS with pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Please login below to download this issue (PDF)